Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics

Hongkai Bao, Yi Guo, Mei H. Chang, Terrence McSweeney, Austin M. Golia, Kelsie Cowman, Rachel Bartash, Brenda I. Anosike, Priya Nori

Research output: Contribution to journalReview articlepeer-review

Abstract

Antimicrobial stewardship programs (ASPs) can be expanded to the outpatient setting to serve as a first line of defense against coronavirus disease 19 (COVID-19) hospitalizations and to reduce the burden on emergency departments and acute-care hospitals. Given the numerous emergency use authorizations of monoclonal antibodies and oral antivirals, ASPs possess the expertise and leadership to direct ambulatory COVID-19 initiatives and transform it into a predominantly outpatient illness. In this review, we summarize the critical role and benefits of an ASP-championed ambulatory COVID-19 therapeutics program.

Original languageEnglish (US)
Article numbere73
JournalAntimicrobial Stewardship and Healthcare Epidemiology
Volume2
Issue number1
DOIs
StatePublished - Apr 29 2022

ASJC Scopus subject areas

  • Infectious Diseases
  • Epidemiology
  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics'. Together they form a unique fingerprint.

Cite this